TransPharma has successful diabetes trial

TransPharma Medical, a Lod, Israel-based company developing transdermal drug delivery technology, has completed a Phase Ia trial of its ViaDerm-GLP1 agonist being developed to treat Type 2 diabetes. The study was designed to evaluate two doses of ViaDerm-GLP1 in healthy volunteers, as compared to a subcutaneous injection of Exenatide (Byetta). The results? “Safe and well-tolerated,” says TransPharma, which is company-speak for “it works.” TransPharma’s ViaDerm drug delivery system incorporates a handheld electronic device, which creates microscopic passageways through the outer layer of the skin allowing for transdermal delivery of a wide variety of drugs from a patch. TransPharma release | ViaDerm overview

Suggested Articles

Purdue's reformulated OxyContin may stop patients from snorting or injecting the drug, but it doesn't curb abuse overall, an FDA panel determined.

Roche is gearing up to launch an eye implant to make its Lucentis AMD drug easier to use. But the drugmaker has even bigger plans for the device.

Delivery specialist IntelGenx struck two deals to develop oral films for prescription psychedelics this summer with Canada's Cybin and ATAI.